利妥昔单抗治疗Richter转化——病例系列
Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
作者信息
Smith Courtney J, Goyal Anmol, Smith Brian R, Lee Dasom, Jensen Alexandria, Alexander Jonathan, Smith Melody, Frank Matthew, Dahiya Saurabh, Miklos David, Bharadwaj Sushma
机构信息
Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USA.
Division of Hematology Stanford University School of Medicine Stanford California USA.
出版信息
EJHaem. 2025 Mar 10;6(2):e270011. doi: 10.1002/jha2.70011. eCollection 2025 Apr.
INTRODUCTION
Richter's transformation (RT) from chronic lymphocytic leukemia (CLL) to lymphoma carries poor prognosis. This case series examines the efficacy of lisocabtagene maraleucel (liso-cel) in six RT patients, highlighting the impact of concurrent ibrutinib therapy.
METHODS
Six patients were with RT who received liso-cel from were included in this single institution case series. Clinical data related to efficacy, safety, CAR-T expansion kinetics, and measurable residual disease were collected.
RESULTS
The best overall response was 83.3%. The four patients who received ibrutinib concurrent with liso-cel therapy continue to show MRD-negative complete response till date. None experienced severe (grade 3+) cytokine release syndrome while 1 had severe (grade 3+) immune-effector cell-associated neurotoxicity syndrome (ICANS). All patients were noted to have in vivo CAR expansion.
CONCLUSION
This series of real cases suggests liso-cel with concurrent ibrutinib may be a promising treatment for RT, warranting further exploration.
引言
慢性淋巴细胞白血病（CLL）向淋巴瘤的里氏转化（RT）预后较差。本病例系列研究了利妥昔单抗（liso-cel）对6例RT患者的疗效，突出了同时使用伊布替尼治疗的影响。
方法
本单机构病例系列纳入了6例接受liso-cel治疗的RT患者。收集了与疗效、安全性、CAR-T扩增动力学和可测量残留疾病相关的临床数据。
结果
最佳总体缓解率为83.3%。4例同时接受伊布替尼和liso-cel治疗的患者至今仍显示微小残留病（MRD）阴性的完全缓解。无一例发生严重（3级以上）细胞因子释放综合征，1例发生严重（3级以上）免疫效应细胞相关神经毒性综合征（ICANS）。所有患者体内均有CAR扩增。
结论
这一系列真实病例表明，liso-cel联合伊布替尼可能是RT的一种有前景的治疗方法，值得进一步探索。
Zotero 插件